The use of immunostimulatory CpG-oligonucleotide DSP30 plus interleukin 2 (IL-2), a CLL B cell-specific mitogen in cultures (4), has improved the success rate of CBA, resulting in the discovery of novel chromosomal aberrations in addition to well-known prognostic genetic markers, such as 13q14, 17p13, and 11q22 deletions, and trisomy 12 (+12). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.